Erythropoietin is not a risk factor for severe retinopathy of prematurity among high risk preterm infants

Retinopathy of prematurity (ROP) is a developmental retinal vaso-proliferative disease and a leading cause of blindness in children. Early gestational age, low birth weight and unregulated oxygen exposure are the main risk factors for the development of ROP. There are conflicting reports of a possib...

Full description

Saved in:
Bibliographic Details
Published in:Early human development 2021-10, Vol.161, p.105440-105440, Article 105440
Main Authors: Bui, Kim Chi T., Ellenhorn, Naomi, Abbasi, Afshan, Villosis, Maria Fe B., Nguyen, Marielle, Truong, Huy, Watson, Tameka, Buchanan, Joanna, Chen, Qiaoling
Format: Article
Language:English
Subjects:
Anemia
Bevacizumab
Blood transfusion
Erythropoietin
Gestational age
Laser ablation
Neonatal infection
Patent ductus
Postnatal steroids
Prematurity
Respiratory support
Retinopathy of prematurity
ROP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Retinopathy of prematurity (ROP) is a developmental retinal vaso-proliferative disease and a leading cause of blindness in children. Early gestational age, low birth weight and unregulated oxygen exposure are the main risk factors for the development of ROP. There are conflicting reports of a possible association between recombinant Erythropoietin (rhEPO) use and an increased risk for the development of ROP. To determine whether rhEPO is an independent risk factor for the development of severe ROP among preterm infants with a gestational age of 23 to 32 weeks and a birth weight
ISSN:0378-3782
1872-6232
DOI:10.1016/j.earlhumdev.2021.105440